イノツズマブオゾガマイシン、イノツズマブ・オゾガマイシン、イノツズマブオゾガミシン

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/01/21 14:16:49」(JST)

wiki en

Inotuzumab ozogamicin (CMC-544) is an antibody-drug conjugate for the treatment of cancers.^[1] It consists of the humanized monoclonal antibody inotuzumab (for CD22), linked to a cytotoxic agent from the class of calicheamicins (which is reflected by 'ozogamicin' in the drug's name).^[2]

This drug is being developed by Pfizer and UCB.

It is undergoing numerous clinical trials,^[3] including two phase II trials for Non-Hodgkin lymphoma (NHL).

A phase III trial in patients with follicular b-cell NHL has been terminated due to poor enrollment.^[4] A Phase III trial in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who were not candidates for intensive high-dose chemotherapy was terminated for futility.^[5]

References

^ Statement On A Nonproprietary Name Adopted By The Usan Council - Inotuzumab ozogamicin, American Medical Association.
^ Takeshita, A; Shinjo, K; Yamakage, N; Ono, T; Hirano, I; Matsui, H; Shigeno, K; Nakamura, S; Tobita, T; Maekawa, M (2009). "CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.". British journal of haematology 146 (1): 34–43. doi:10.1111/j.1365-2141.2009.07701.x. PMID 19388933.
^ http://clinicaltrials.gov/ct2/results?term=Inotuzumab+ozogamicin
^ Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
^ http://pfizer.newshq.businesswire.com/press-release/pfizer-discontinues-phase-3-study-inotuzumab-ozogamicin-relapsed-or-refractory-aggress

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人における再発性および難治性の急性リンパ芽球性白血病の治療 treatment of relapsed or refractory acute lymphoblastic leukemia in adults

English Journal

Antibody therapy for acute lymphoblastic leukemia.

Portell CA, Advani AS.SourceDivision of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA. portelc@ccf.org
Current hematologic malignancy reports.Curr Hematol Malig Rep.2012 Jun;7(2):153-9.
Advances in chemotherapy administration have made acute lymphoblastic leukemia (ALL) a curable disease; however, most patients will relapse, despite readily attaining a complete remission. Treatment of relapse has shown dismal results with little advances made in the recent decades. Antigenic-direct
PMID 22422550

Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia.

Thomas X.SourceHospices Civils de Lyon, Lyon-Sud Hospital, Hematology Department, Pavillon Marcel Bérard, Bat.1G, 69495 Pierre-Bénite, France. xavier.thomas@chu-lyon.fr
Expert opinion on investigational drugs.Expert Opin Investig Drugs.2012 Jun;21(6):871-8. Epub 2012 Apr 16.
INTRODUCTION: Inotuzumab ozogamicin (CMC-544) is a humanized anti-CD22 monoclonal antibody conjugated with calicheamicin. Preclinical data indicate activity against B-cell tumors and early results from clinical trials indicate activity against B-cell lineage acute lymphoblastic leukemia (ALL). AREAS
PMID 22500551

Japanese Journal

新規抗体/薬物複合体によるリンパ系腫瘍の治療 : イノツズマブ・オゾガマイシンとブレンツキシマブ・ベドチン (特集新規ターゲットおよび医薬品による血液がん治療の新たな展開)

薄井紀子
血液内科 70(2), 186-191, 2015-02
NAID 40020385039

CD22,CD33を標的としたがん治療の展望 (特集注目すべき新標的と期待される次世代抗悪性腫瘍薬)

畠清彦
腫瘍内科 13(6), 782-785, 2014-06
NAID 40020137183

急性リンパ芽球性白血病に対して臨床試験実施中の抗体薬 : 抗CD22ADCとblinatumomab (特集血液腫瘍に対する抗体医薬のさらなる進展)

薄井紀子
血液内科 68(4), 434-440, 2014-04
NAID 40020085456

Related Pictures

★リンクテーブル★

リンク元	「イノツズマブオゾガミシン」「イノツズマブオゾガマイシン」「イノツズマブ・オゾガマイシン」
関連記事	「ozogamicin」

「イノツズマブオゾガミシン」

Inotuzumab ozogamicin
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD22
Identifiers
CAS Number	635715-01-4
ATC code	None
UNII	P93RUU11P7
KEGG	D08933
Chemical data
Formula	C6518H10002N1738O2036S42
Molecular mass	150,000 Daltons
(what is this?) (verify)